Summary

Europe Early Toxicity Testing Market is valued at approximately USD 253.50 million in 2023 and is anticipated to grow with a healthy growth rate of more than 8.10% over the forecast period 2024-2032. Early toxicity testing represents a pivotal stage in the drug development continuum, focusing on evaluating the potential adverse effects of novel compounds or substances on living organisms. This initial assessment serves to identify safety concerns and guide subsequent research and development endeavors. Through early toxicity testing, researchers can effectively manage risks and refine the safety profile of pharmaceutical candidates before progressing to subsequent developmental phases. The augmented emphasis on research and development and amplified investments in innovative drug and technology development targeted at addressing life-threatening diseases is a key trend that is supporting the growth of the Europe Early Toxicity Testing Market.

The Europe Early Toxicity Testing Market is experiencing substantial growth driven by heightened demand for safety and efficacy evaluations of new drugs and chemicals. Stringent regulations imposed by the European Union to ensure consumer safety further propel market expansion. Additionally, increasing demand for animal-free testing methods has spurred the development of more accurate and cost-effective in-vitro and in-silico testing approaches, surpassing traditional animal testing. The market is bolstered by rising demand for personalized medicine, fostering the adoption of innovative technologies such as organ-on-a-chip and 3D cell culture for safety evaluations. Furthermore, the surge in predictive toxicology demand has led to advanced technologies such as artificial intelligence and machine learning for toxicity prediction. However, the significant costs associated with comprehensive early toxicity testing, particularly for smaller companies with limited financial resources, pose a keybarrier. Moreover, stringent regulatory requirements by agencies such as the European Medicines Agency delay market entry, potentially impeding further growth.

The key countries considered for the Europe Early Toxicity Testing market study includes UK, Germany, France, Italy, Spain, and Rest of Europe. In 2023, Germany leads the European market. Strong growth is anticipated in this region over the forecast period, driven by factors including heightened awareness and favorable reimbursement policies. Increased public awareness and rising demand for toxicity testing devices are expected to further bolster market growth. Whereas, the United Kingdom is expected to grow with the highest CAGR during the forecast period 2024-2032.

Major market player included in this report are:
Eurofins Scientific SE
Evotec A.G.
Merck KGaA
Company 4
Company 5
Company 6
Company 7
Company 8
Company 9
Company 10

The detailed segments and sub-segment of the market are explained below:

By Technique
In Vivo
In Vitro
In Silico

By Toxicity Endpoint
Genotoxicity
Dermal Toxicity
Skin Toxicity
Ocular Toxicity
Phototoxicity
Others

By End Use
Pharmaceutical Industry
Cosmetic Industry
Chemical Industry
Food Industry
Others
By Region:
Europe
UK
Germany
France
Spain
Italy
ROE

Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032

Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and Country level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

ページTOPに戻る

Table of Contents

Chapter 1. Europe Early Toxicity Testing Market Definition and Research Assumptions
1.1. Research Objective
1.2. Market Definition
1.3. Research Assumptions
1.3.1. Inclusion & Exclusion
1.3.2. Limitations
1.3.3. Supply Side Analysis
1.3.3.1. Availability
1.3.3.2. Infrastructure
1.3.3.3. Regulatory Environment
1.3.3.4. Market Competition
1.3.3.5. Economic Viability (Consumer’s Perspective)
1.3.4. Demand Side Analysis
1.3.4.1. Regulatory frameworks
1.3.4.2. Technological Advancements
1.3.4.3. Environmental Considerations
1.3.4.4. Consumer Awareness & Acceptance
1.4. Estimation Methodology
1.5. Years Considered for the Study
1.6. Currency Conversion Rates

Chapter 2. Executive Summary
2.1. Europe Early Toxicity Testing Market Size & Forecast (2022- 2032)
2.2. Regional Summary
2.3. Segmental Summary
2.3.1. By Technique
2.3.2. By Toxicity Endpoint
2.3.3. By End Use
2.4. Key Trends
2.5. Recession Impact
2.6. Analyst Recommendation & Conclusion
Chapter 3. Europe Early Toxicity Testing Market Dynamics
3.1. Market Drivers
3.2. Market Challenges
3.3. Market Opportunities
Chapter 4. Europe Early Toxicity Testing Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Europe Early Toxicity Testing Market Size & Forecasts by Technique 2022-2032
5.1. In Vivo
5.2. In Vitro
5.3. In Silico
Chapter 6. Europe Early Toxicity Testing Market Size & Forecasts by Toxicity Endpoint 2022-2032
6.1. Genotoxicity
6.2. Dermal Toxicity
6.3. Skin Toxicity
6.4. Ocular Toxicity
6.5. Phototoxicity
6.6. Others
Chapter 7. Europe Early Toxicity Testing Market Size & Forecasts by Toxicity Endpoint 2022-2032
7.1. Pharmaceutical Industry
7.2. Cosmetic Industry
7.3. Chemical Industry
7.4. Food Industry
7.5. Others
Chapter 8. Europe Early Toxicity Testing Market Size & Forecasts by Country 2022-2032
8.1. U.K. Early Toxicity Testing Market
8.1.1. Technique breakdown size & forecasts, 2022-2032
8.1.2. Toxicity Endpoint breakdown size & forecasts, 2022-2032
8.1.3. End Use breakdown size & forecasts, 2022-2032
8.2. Germany Early Toxicity Testing Market
8.3. France Early Toxicity Testing Market
8.4. Spain Early Toxicity Testing Market
8.5. Italy Early Toxicity Testing Market
8.6. Rest of Europe Early Toxicity Testing Market
Chapter 9. Competitive Intelligence
9.1. Key Company SWOT Analysis
9.1.1. Company 1
9.1.2. Company 2
9.1.3. Company 3
9.2. Top Market Strategies
9.3. Company Profiles
9.3.1. Eurofins Scientific SE
9.3.1.1. Key Information
9.3.1.2. Overview
9.3.1.3. Financial (Subject to Data Availability)
9.3.1.4. Product Summary
9.3.1.5. Market Strategies
9.3.2. Evotec A.G.
9.3.3. Merck KGaA
9.3.4. Company 4
9.3.5. Company 5
9.3.6. Company 6
9.3.7. Company 7
9.3.8. Company 8
9.3.9. Company 9
9.3.10. Company 10
Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes